SPONSORSHIP ALLIANCE NEWS
The 2025 Global Radiotherapy Impact Report brings together leading experts from across radiation oncology, including voices well-known to the RSS community, to highlight how advanced radiotherapy, including SBRT and SRS, is transforming cancer care worldwide. Convened by Elekta, the report illustrates compelling clinical outcomes, patient quality of life, and the growing evidence behind high-precision, adaptive, and ablative treatments. It also underscores an urgent truth: expanding access to radiotherapy could save up to 1 million lives each year. RSS members can use this report to stay informed, advocate, and advance the future of precision radiation medicine.
More than 300 people came together for the Leksell Gamma Knife Society Meeting in Stockholm from October 19-21, 2025, chaired by this year's Scientific President Dr Veronica Chiang, director of the Gamma Knife Center at Yale New Haven Hospital. Innovators, scientists, and clinicians from more than 45 countries participated in three days of learning and networking to discuss the future of radiosurgery. The topics covered ranged from Biologically Effective Dose (BED) and AI applications to immobilization techniques and indication-specific deep dives. The future looks promising, especially with five individuals receiving the Young Investigator Award for their outstanding abstracts in various categories. Combining science and technology with passion for people to live longer, this incredible event builds on the momentum to shape the next 50 years of radiosurgery.
This year, this dedicated and pioneering community also celebrated that together they have treated more than two million patients with Leksell Gamma Knife. Read more at the link provided.
Brain tumors are the most common solid neoplasms in pediatric patients. However, treatment options remain limited in cases of local recurrence, metastasis, or inoperability. Stereotactic radiosurgery (SRS) offers a potential treatment option in these scenarios. This multicenter study reviews the indications and outcomes of SRS in treating pediatric central nervous system (CNS) lesions.
While SABR is associated with excellent local control of primary renal cell carcinoma (RCC), outcomes based on clear cell RCC (ccRCC) and non-clear cell RCC (nccRCC) histologies are not well defined. This retrospective study's objective is to report the outcomes following SABR for uncommon subtypes of primary RCC.
Adrenal metastases are frequently diagnosed in patients with common solid tumors. Surgical adrenalectomy has historically been used for their management. However, stereotactic body radiation therapy (SBRT) has emerged as a safe and effective alternative. Careful treatment planning is essential, considering multiple factors such as tumor size and location, motion management, dose and fractionation, and proximity to adjacent organs at risk. This case-based practice guide and review provides an overview of SBRT for the management of adrenal tumors, with a particular focus on adrenal metastases.
A radiation oncologist’s breakthrough in delivering ultra-fast radiation may make cancer treatment more effective—and less damaging.
Stanford’s Department of Radiation Oncology is breaking new ground in cancer treatment with RefleXion's technology. This technology utilizes positron emission tomography (PET) imaging to deliver precise, targeted radiation therapy. Spearheaded by Lucas Vitzthum, MD, Clinical Associate Professor of Radiation Oncology, and Murat Surucu, PhD, Clinical Professor of Radiation Oncology and Chief of Clinical Physics, this approach allows for real-time tracking of tumors during treatment.
Varian, a Siemens Healthineers company, has announced the successful completion of enrollment and treatment in its FAST-02 (Flash Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax) clinical trial. The FAST-02 study targets painful bone metastases in the thoracic region and represents a significant step toward bringing this investigational radiotherapy treatment into clinical practice.
In just 24 months, Elekta has achieved its 30th Esprit installation across the Americas and over 50 worldwide since its 2022 launch, expanding global access to precision radiosurgery. Leksell Gamma Knife continues to lead the way with mask-based and frame-based options, superior precision for benign and functional indications, and the industry’s lowest extracranial dose. As demand grows for repeat radiosurgery, AI integration, and efficient, personalized treatments, Elekta is shaping the future of patient-centered care.
Read the full article to see how we’re redefining brain radiosurgery for the next generation of clinicians and patients.
Elekta recently announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to include refractory, intractable mesial temporal lobe epilepsy (MTLE) in adults among its indications for use with the company’s Leksell Gamma Knife radiosurgery system. Gamma Knife surgery treats refractory, drug-resistant MTLE by precisely focusing 192 beams of gamma radiation to target and disrupt the exact region of the brain responsible for epileptic seizures, potentially reducing frequency or eliminating them without opening the skull. Read more about this exciting announcement at www.elekta.com/gammaknife. Leksell Gamma Knife has U.S. FDA 510(k) clearance for the new indication of “drug resistant epilepsy” with limited global availability.
